<DOC>
	<DOCNO>NCT00821353</DOCNO>
	<brief_summary>Paroxysmal chronic atrial fibrillation ( AF ) develop 20- 25 % adult patient hypertrophic cardiomyopathy ( HCM ) represent important complication clinical course disease , adverse long-term consequence functional status outcome . Therefore , aggressive therapeutic strategy indicate restore maintain sinus rhythm ( SR ) patient HCM . Nevertheless , pharmacologic prevention AF recurrence challenge limited long-term efficacy potentially hazardous side effect available treatment option . Currently radiofrequency catheter ablation ( RFCA ) AF successfully use clinical practice . However , comparison efficacy safety two therapeutic option do till randomized manner group patient . Thus , aim present study compare efficacy safety RFCA vs. antiarrhythmic drug therapy patient HCM AF .</brief_summary>
	<brief_title>Antiarrhythmic Therapy Versus Catheter Ablation Atrial Fibrillation Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Patients hypertrophic cardiomyopathy paroxysmal chronic atrial fibrillation Severe hear failure ( NYHA IV ) Left ventricular ejection fraction &lt; 0.30 Left atrial diameter &gt; 65 mm Age &gt; 70 year Contraindication anticoagulation warfarin Presence mechanical prosthetic valve Presence leave atrial thrombus TEE CT Woman currently pregnant Renal failure ( GFR &lt; 30 ml/min ) Hepatic failure Untreated hypothyroidism hyperthyroidism LVOT gradient &gt; 50 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>RF ablation</keyword>
	<keyword>Antiarrhythmic drug</keyword>
</DOC>